Adcetris (brentuximab vedotin) / Takeda, Pfizer - LARVOL DELTA

Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial. (PubMed, J Clin Oncol) - P3 | "PET-guided BrECADD in older patients is feasible and effective. With a PFS rate on par with that of younger patients, short duration, and limited anthracycline exposure, BrECADD is a valuable treatment option also for older patients with AS-cHL."

Journal • P2 data • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Leukopenia • Lymphoma • Neutropenia • Oncology • Thrombocytopenia

Five cases of cutaneous T-cell lymphoma treated with brentuximab vedotin (JSCS 2025) - No abstract available

Clinical • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Brentuximab vedotin was effective in treating mycosis fungoides with small intestinal and lumbar metastases (JSCS 2025) - No abstract available

Cutaneous T-cell Lymphoma • Dermatology • Mycosis Fungoides • Oncology

Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial. (PubMed, Lancet Oncol) - P3 | "Compared with eBEACOPP, BrECADD led to significantly better gonadal function recovery, as well as higher parenthood rates (significantly so in men). These findings support BrECADD as preferred first-line therapy, especially for patients wishing to preserve fertility."

Journal • P3 data • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Advancements in Cutaneous T-Cell Lymphoma Treatment: Unveiling Novel Therapeutic Avenues and Clinical Implications. (PubMed, Am J Clin Oncol) - "This review emphasizes the necessity for ongoing research and individualized treatment plans while highlighting the promise of these cutting-edge techniques to enhance outcomes for patients with advanced CTCL."

Journal • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • CCR4 • IL15 • IL9 • TNFRSF8

BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma (clinicaltrials.gov) - P2 | N=48 | Recruiting | Sponsor: University of Miami | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

New nonchemotherapy treatment options for cutaneous T-cell lymphomas- an update. (PubMed, Expert Rev Anticancer Ther) - "Targeted therapies including brentuximab vedotin, lacutamab, denileukin diftitox, and mogamulizumab have shown activity in registrational trials. Novel agents which modulate tumor microenvironment and upregulate tumor-specific immune responses have been in clinical trials, including bispecific antibodies recruiting immune effectors, agents eradicating suppressive microenvironments, and engineered T cells targeting tumor epitopes. Checkpoint inhibitors may play a role in MF/SS but their role has not been well defined and they may induce hyper progression."

Journal • Review • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma

Molecularly targeted therapy strategies for adult T-cell leukemia/lymphoma (PubMed, Rinsho Ketsueki) - "Lenalidomide, an oral anticancer drug classified as an immunomodulator, showed an overall response rate of 46% in a phase II clinical trial in relapsed ATL. The antibody therapy mogamulizumab showed an overall response rate of 50% in a phase II trial of relapsed C-C motif chemokine receptor 4-positive ATL. Brentuximab vedotin has yet to show clear evidence of efficacy due to the limited number of patients enrolled in phase II trials...The EZH1/2 inhibitor valemetostat showed a response rate of 48% in a phase II trial in relapsed/refractory aggressive ATL. The histone acetylation inhibitor tucidinostat also exhibited efficacy in ATL, with an objective response rate of 30.4%. This review focuses on the abovementioned molecular-targeted agents, which are all currently used in Japan."

Journal • Review • Adult T-Cell Leukemia-Lymphoma • Gene Therapies • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Oral Cancer • CCR4 • EZH2

Challenges of CD30 expression and its impact on targeted treatment responses in non-Hodgkin lymphoma: New perspectives for evaluation and validation. (PubMed, Pathol Res Pract) - "Brentuximab vedotin (BV), a CD30-directed antibody-drug conjugate (ADC), has received approval for clinical use in patients with cHL and ALCL, demonstrating remarkable efficacy...The cause of this is multifactorial, such as the intra and interlesional heterogeneity of CD30 expression in tumor samples, the alternative secondary mechanisms of action of BV, and the IHC methodology, which is based on a semi-quantitative assay with limitation to detect lower levels of CD30 expression. In this review, we describe the current expert consensus and guidelines for evaluating CD30 expression by IHC in lymphoma biopsies, discuss ongoing controversies, and provide new perspectives on the direction of evaluation and validation of CD30 expression in the future."

Journal • Review • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • TNFRSF8

Frontline brentuximab vedotin-based therapy for newly diagnosed classical Hodgkin lymphoma: a meta-analysis of randomized controlled trials (Frontiers) - "Pooled data from four RCTs (N = 3591 patients) demonstrated significant PFS improvement with BV-based regimens (HR: 0.58, 95% CI: 0.44 to 0.77, P < 0.001), with consistent benefits across subgroups stratified by disease stage, gender, age, and International Prognostic Score (IPS). Although interim PET-2 negativity rates showed only a non-significant trend favoring BV (RR: 1.02, 95% CI: 0.99 to 1.04, P = 0.286), end-of-treatment complete metabolic response rates were significantly higher (RR: 1.03, 95% CI: 1.00 to 1.06, P = 0.024). Safety analyses revealed comparable incidences of grade ≥3 AEs between groups (RR: 1.05, 95% CI: 0.80 to 1.37, P = 0.739), with no increased risk of peripheral neuropathy or secondary malignancies...our meta-analysis demonstrates that incorporation of BV into frontline therapy for classical HL provides significant PFS benefits and improved end-oftreatment metabolic responses, with manageable toxicity."

Retrospective data • Hodgkin Lymphoma

Treatment optimisation trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 6 cycles of escalated BEACOPP with 6 cycles of BrECADD. (ANZCTR) - P3 | N=1585 | Completed | Sponsor: University of Cologne | Active, not recruiting ➔ Completed

Trial completion • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Incidence of Clinically Significant Neutropenia and Complications Related to Antibody-Drug Conjugates: A Real-Word Study at University of California (MASCC-ISOO 2025) - "Methods A multi-center retrospective study utilized UC Health Data Warehouse records of patients receiving at least one dose of the ten most-used ADCs between January 2012 and August 2024: fam-trastuzumab deruxtecan, ado-trastuzumab emtansine, brentuximab vedotin, sacituzumab govitecan, enfortumab vedotin, gemtuzumab ozogamicin, inotuzumab ozogamicin, polatuzumab vedotin, belantamab mafodotin, and tisotumab vedotin. Patient distribution and primary outcomes Table 3. Secondary outcomes Conclusions The most commonly used ADCs in contemporary practice, such as fam-trastuzumab deruxtecan, and ado-trastuzumab emtansine, were associated with reasonably low rates of febrile neutropenia and related events."

Clinical • Anemia • Febrile Neutropenia • Neutropenia • Oncology

PREDICTORS FOR ANTIBODY-DRUG CONJUGATES (ADCS) ASSOCIATED CLINICALLY SIGNIFICANT NEUTROPENIA AT UNIVERSITY OF CALIFORNIA HOSPITALS (MASCC-ISOO 2025) - "The study focused on the ten most commonly used ADCs: fam-trastuzumab deruxtecan, ado-trastuzumab emtansine, brentuximab vedotin, sacituzumab govitecan, enfortumab vedotin, gemtuzumab ozogamicin, inotuzumab ozogamicin, polatuzumab vedotin, belantamab mafodotin, and tisotumab vedotin. Conclusions Selected ADCs are associated with significant risks of severe neutropenia. These findings highlight the importance of identifying patients who are predisposed to these adverse effects and implementing tailored management strategies."

Clinical • Anemia • Breast Cancer • Hepatology • Liver Failure • Neutropenia • Oncology

Comparison of Contemporary Radiotherapy Approaches in Combined Modality Treatment on Pediatric High-Risk Classic Hodgkin Lymphoma Study: AHOD 1331. (PubMed, Int J Radiat Oncol Biol Phys) - "Selective use of RT combined with chemotherapy, including brentuximab vedotin, led to excellent outcomes for pediatric patients with high-risk HL. Proton therapy utilization increased during the study, showing similar disease control and toxicity outcomes as 3D-CRT and IMRT. Long-term follow-up is essential to evaluate the risks of secondary malignancies and cardiac toxicity across radiation techniques."

Journal • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Pediatrics

Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) (clinicaltrials.gov) - P3 | N=304 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Trial completion date: Jul 2025 ➔ Oct 2025 | Trial primary completion date: Jul 2025 ➔ Oct 2025

Trial completion date • Trial primary completion date • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Recurrent Composite Lymphoma in an Elderly Man: A Case of Marginal Zone Lymphoma With Classic Hodgkin Features Treated With Brentuximab and Immunotherapy. (PubMed, Cureus) - "The clinical course further highlights the importance of personalized therapy selection based on age, comorbidities, and histological features. This case also contributes to the limited literature on real-world outcomes in patients with CL and underscores the need for future prospective studies and biomarker-driven treatment approaches in this rare entity."

IO biomarker • Journal • B Cell Lymphoma • Classical Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Epstein-Barr Virus Infections • Follicular Lymphoma • Geriatric Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Brentuximab vedotin monotherapy for CD30-positive adult T-cell leukemia/lymphoma with HTLV-1-infected Hodgkin and Reed-Sternberg-like cells. (PubMed, J Clin Exp Hematop) - "Eight months have passed since the end of treatment, and the disease has not progressed. The positive results of this study suggest that BV monotherapy could be considered a viable treatment option for older or frail patients with CD30-positive ATL, particularly those with HTLV-1-infected HRS-like cells, who may not be able to tolerate standard multi-agent chemotherapy."

Journal • Monotherapy • Adult T-Cell Leukemia-Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • TNFRSF8

Co-occurrence of myositis and neuropathy after anti-CD30 therapy in a late-adolescent Hodgkin lymphoma patient. (PubMed, Acta Neuropathol Commun) - "Myositis following BV therapy has not been reported. Findings suggest an immune-mediated mechanism with B-cell involvement. Given the response to IVIG, B-cell-directed therapies may be beneficial. This case identifies BV-induced myositis as a novel irAE."

IO biomarker • Journal • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma • Metabolic Disorders • Myositis • Oncology • Pain • HPRT1 • NCAM1

Alk-positive anaplastic large cell Lymphoma: First documented case of primary mandibular involvement in a 12-Year-Old male. (PubMed, Oral Oncol) - "The patient was treated with Brentuximab Vedotin in combination with the R-CHOP regimen and showed an excellent clinical response with gradual resolution of swelling. This case highlights the diagnostic complexity of undifferentiated mandibular tumors in pediatric patients and emphasizes the importance of integrating morphology, immunophenotyping, and systemic evaluation to identify rare presentations of peripheral T-cell lymphomas."

Journal • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK • PTPRC • TNFRSF8

RESULTS OF PROSPECTIVE OBSERVATIONAL STUDY OF PEMBOLIZUMAB BIOSIMILAR BCD-201 IN PATIENTS WITH REFRACTORY CLASSICAL HODGKIN'S LYMPHOMA (ICML 2025) - "Fifty percent of patients had received four or more lines of therapy; none of the patients met criteria to undergo high doses chemotherapy followed by autologous stem cell transplantation; one patient was refractory to brentuximab vedotin. BCD-201 pembrolizumab biosimilar demonstrated high ORR, overall survival and safety profiles."

Clinical • Observational data • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • PROCR

TARGETED IMMUNOTHERAPY IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA, A SINGLE CENTER EXPERIENCE (ICML 2025) - "We have combined the use of the antibody-drug conjugate brentuximab vedotin (Bv) to target reed-sternberg cells along with the anti-CD20 antibody rituximab (RTX) and checkpoint inhibitor nivolumab (N) targeting the immune microenvironment added to risk-adapted chemotherapy in newly diagnosed CAYA cHL patients... All patients received 2 cycles of Bv, doxorubicin, vinblastine, dacarbazine, and RTX (Bv-AVD-R)... The addition of immunotherapy to a reduced chemotherapy backbone is safe, effective and well tolerated. Targeting the HRS cell as well as the tumor microenvironment and PD1/PD-L1 axis is a promising approach in CAYA with cHL and may allow for reduction in anthracycline and radiation exposure, thus limiting short- and long-term adverse effects. Keyword: non-Hodgkin (Pediatric, Adolescent, and Young Adult)"

Clinical • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

ANALYSIS OF BRENTUXIMAB VEDOTIN USE IN THE SETTING OF ADULTS PATIENTS WITH POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS AMONG THE FRENCH NATIONAL K-VIROGREF DATABASE (ICML 2025) - "Almost, 30%–60% of patients (pts) with PTLD achieve complete remission (CR), with 4 Rituximab (R) infusions induction, followed by consolidation with 4 R infusions in case of CR following the induction, or 4 R-CHOP for pts in relasped-refactory (RR) disease...7 pts received mBv while, 8 received Bvco (CHP n = 3, ICE n = 1, AVD n = 1, ESHAP n = 1, Bendamustine n = 1, Cyclophosphamide n = 1)... To our knowledge, this is the largest real life series presented to date and evaluating, use of Bv in pts with PTLD. Our data confirm the good tolerance of Bv in this population of pts regardless the histology. Interestingly, efficacy of Bvco, is very encouraging and should be confirmed in larger cohort of PTLD pts."

Clinical • Post-transplantation • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • CD20

A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF BELEODAQ-CHOP OR FOLOTYN-COP TO THE CHOP REGIMEN IN FRONTLINE PTCL (CRESCENDO TRIAL) (ICML 2025) - P3 | "Anticipated enrollment is 504 patients, age 318 with newly diagnosed measurable PTCL (various subtypes excluding cutaneous T cell lymphomas and ALCLs eligible for brentuximab vedoitin), ECOG status ≤ 2, and eligible to receive Bel or Fol along with standard CHOP regimen...Bel and Fol will be added separately to standard CHOP or COP (CHOP without doxorubicin) for 6 treatment cycles of 21 days...Tumor assessments will be performed every 3 cycles and at end-of-treatment, then every 3 months for 3 years for patients with CR, PR or SD, and every 6 months thereafter until PD or death. Part 1 recruitment began Q1 of 2024."

Clinical • P3 data • Cutaneous T-cell Lymphoma • Lymphoma • Peripheral T-cell Lymphoma

INFECTIOUS COMPLICATIONS OF AGENTS USED IN T-CELL LYMPHOMAS: A DISPROPORTIONALITY ANALYSIS USING THE FAERS DATABASE (EHA 2025) - "The public dashboard of FAERS was queried for reports of infections due to herpes simplex virus (HSV), varicella zoster virus (VZV), cytomegalovirus (CMV), pneumocystis jiroveci (PJP) and cases of hepatitis B (HepB) reactivation and neutropenia associated with mogamulizumab, brentuximab vedotin, vorinostat, romidepsin, praletexate, methotrexate, peginterferon alpha-2a (PEG-IFN alfa-2a) and alemtuzumab when used for the indication of any T-cell lymphoma. Analysis of the FAERS database revealed variability in the reported infectious complications of commonly used agents for TCLs. Among all agents, alemtuzumab had the highest RORs for all infections while vorinostat had statistically significant RORs only for VZV-related infections and neutropenia. Romidepsin, which is a histone deacetylase inhibitor like vorinostat, had RORs that were unexpectedly higher than vorinostat and were comparable with other agents for CMV, HSV and PJP-related infections and neutropenia."

Cutaneous T-cell Lymphoma • Cytomegalovirus Infection • Hematological Disorders • Hematological Malignancies • Hepatitis B • Hepatology • Herpes Simplex • Herpes Zoster • Infectious Disease • Lymphoma • Neutropenia • Oncology • T Cell Non-Hodgkin Lymphoma • Varicella Zoster

REAL WORLD OUTCOMES OF HISTONE DEACETYLASE INHIBITORS IN RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA: A MULTICENTRIC RETROSPECTIVE STUDY IN ARGENTINA (ICML 2025) - "Romidepsin approval was withdrawn after lack of benefit in combination with CHOP in 1st line, and no confirmatory studies supporting Belinostat have been published...9 pts (42.9%) received ≥ 4 systemic therapies before HDACi, including Lenalidomide (6 pts) and Brentuximab (8 pts)... This retrospective study highlights the RWO of treatment with HDACi in R/R PTCL in Argentina. Survival rates are similar to those published in pivotal trials despite being heavily pretreated pts. No significant prognostic factors were identified based on histological subtype or number of prior treatments."

Epigenetic controller • Real-world • Real-world evidence • Retrospective data • Hematological Malignancies • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma